ISRCTN21056528 https://doi.org/10.1186/ISRCTN21056528

Investigation of the anti-inflammatory effects of simvastatin in a human lipopolysaccharide induced model of acute lung injury

Submission date 29/04/2008	**Recruitment status** No longer recruiting	[_] Prospectively registered [_] Protocol [_] Statistical analysis plan [X] Results [_] Individual participant data
Registration date 09/06/2008	**Overall study status** Completed	
Last Edited 30/06/2009	**Condition category** Respiratory	

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Dr Danny McAuley

Contact details
Intensive Care Unit
Royal Victoria Hospital
Grosvenor Road
Belfast
United Kingdom
BT12 6BA

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers
060778SE-A

Study information

Scientific Title

Study objectives
Treatment with a clinically relevant dose of simvastatin will reduce pulmonary inflammation induced by lipopolysaccharide (LPS) inhalation in humans.

Ethics approval required
Old ethics approval format

Ethics approval(s)
Office for Research Ethics Committees Northern Ireland (ORECNI). Date of approval: 25/10/2006 (ref: 06/NIR02/91)

Study design
Prospective, randomised, double-blind, placebo-controlled trial.

Primary study design
Interventional

Secondary study design
Randomised controlled trial

Study setting(s)
Not specified

Study type(s)
Treatment

Participant information sheet

Health condition(s) or problem(s) studied
Acute lung injury (ALI)

Interventions
Subjects will be randomised to the following three arms:
Arm 1: Simvastatin 40 mg enterally for 4 days prior to inhalation of LPS
Arm 2: Simvastatin 80 mg enterally for 4 days prior to inhalation of LPS
Arm 3: Placebo enterally for 4 days prior to inhalation of LPS

Intervention Type
Drug

Phase
Not Specified

Drug/device/biological/vaccine name(s)
simvastatin

Primary outcome measure
Reduction in broncho alveolar lavage (BAL) Interleukin-8 (IL8) concentration at 6 hours

Secondary outcome measures
1. To investigate whether treatment with simvastatin will modulate the following:
1.1. Alveolar inflammatory response at 6 hours
1.2 Plasma inflammatory response at 24 hours
1.3. Alveolar matrix metalloproteinase activity at 6 hours
1.4. Intracellular signalling in the alveolar space at 6 hours
1.5. Indices of alveolar epithelial and endothelial function and injury at 6 hours
2. To determine the potential mechanisms by which simvastatin may be beneficial in ALI

Overall study start date
02/08/2006

Completion date
05/11/2009

Eligibility

Key inclusion criteria
Healthy subjects, both males and females

Participant type(s)
Patient

Age group
Adult

Sex
Both

Target number of participants
30

Key exclusion criteria
1. Age <18 years
2. Creatinine kinase (CK) >5 times upper limit of normal
3. Known active liver disease
4. Alcohol abuse or abnormal liver function tests: transaminases > 3 times upper limit of normal
5. Renal impairment (calculated creatinine clearance less than 60 mL/minute)
6. History of asthma, known lactose intolerance
7. Participation in other trials within the past 30 days
8. Pregnancy, breast-feeding or women of childbearing potential not using adequate contraception;
9. Current treatment with statins
10. Known hypersensitivity to the study medication
11. Previous adverse reaction to statins
12. Concomitant use of fibrates or other lipid-lowering therapy
13. Concomitant use of itraconazole, ketoconazole, erythromycin, clarithromycin, telithromycin,

HIV protease inhibitors, nefazodone, grapefruit juice, cyclosporine, danazol, amiodarone, verapamil or diltiazem
14. Consent declined

Date of first enrolment
02/08/2006

Date of final enrolment
05/11/2009

Locations

Countries of recruitment
Northern Ireland

United Kingdom

Study participating centre
Intensive Care Unit
Belfast
United Kingdom
BT12 6BA

Sponsor information

Organisation
Belfast Health and Social Care Trust (UK)

Sponsor details
51 Lisburn Road
Belfast
Northern Ireland
United Kingdom
BT9 7AB
+44 (0)28 90 329241
rosemary.mcveigh@belfasttrust.hscni.net

Sponsor type
Hospital/treatment centre

Website
http://www.belfasttrust.hscni.net

ROR
https://ror.org/02tdmfk69

Funder(s)

Funder type
Government

Funder Name
Intensive Care Society, Young Investigator's Award (UK)

Funder Name
REVIVE (UK)

Funder Name
Northern Ireland Health and Social Services Central Services Agency (UK)

Results and Publications

Publication and dissemination plan
Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

IPD sharing plan summary
Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	15/06/2009		Yes	No